Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
This study has been completed.
Study NCT00013585 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: March 22, 2001 Last Updated: August 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cognition Disorders
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Disease
Infection
More general conditions related to this trial
Delirium, Dementia, Amnestic, Cognitive Disorders
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Mental Disorders
Pathologic Processes
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Selegiline hydrochloride
Additional drug interventions recognized in this trial
Selegiline
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Monoamine Oxidase Inhibitors
Neuroprotective Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Neurological Disorders and Stroke (NINDS)
Neurologic AIDS Research Consortium (NARC)
Back to top of Main Content
